Accessibility Menu
Knight Therapeutics logo

Knight Therapeutics(OTC) KHTRF

Market Cap$689.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)+27%
5 Year+72%
1 Year+57%
1 Month-1%
$7.03
-0.41%
-0.03Today
Knight Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 7.032026-07-31
Knight Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.72%USD 6.912026-07-24
1 month-0.99%USD 7.102026-07-01
3 month+30.04%USD 5.402026-05-01
Year to date+61.49%USD 4.352025-12-31
1 year+56.81%USD 4.482025-07-31
3 year+91.94%USD 3.662023-07-31
5 year+71.71%USD 4.092021-07-30
Since inception+26.99%USD 5.532014-04-03

Knight Therapeutics Financials at a Glance

Market Cap

$689.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$510.90M

Net Income (TTM)

CA$5.43M

EPS (TTM)

$0.04

P/E Ratio

165.68

Dividend

$0.00

Beta (Volatility)

0.07 (Low)

Price

$7.03

Volume

7,900

Open

$7.03

Previous Close

$7.03

Daily Range

$7.03 - $7.03

52-Week Range

$4.07 - $7.40

Estimated Earnings Date

Aug 6, 2026

KHTRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Knight Therapeutics

Knight Therapeutics Inc. is a specialized pharmaceutical company focused on the development, acquisition, and distribution of a diverse range of pharmaceutical products and medical devices. The company operates primarily in Canada and Latin America, offering innovative treatments for various medical conditions.

Products and Services
  • Offers treatments for cancer, including Nerlynx and Tafasitamab
  • Provides medications for chronic conditions like diabetes and multiple myeloma
  • Engages in financing for life science companies and venture capital funds
Growth Outlook
  • Recent quarterly revenue increased to CAD 148.8 million, up from CAD 133.0 million
  • Gross profit margin improved to 36.7% in Q1 2026, indicating operational efficiency
  • Strong cash flow from operations of CAD 40.6 million supports future investments
Financial Highlights
  • Net income for Q1 2026 reached CAD 13.2 million, reflecting positive earnings
  • Current ratio stands at 2.32, indicating strong liquidity position
  • Market capitalization is approximately CAD 688 million, showcasing growth potential
Knight Therapeutics Inc. has established itself as a key player in the pharmaceutical industry, with a robust portfolio of products addressing critical health needs. The company's focus on innovative therapies and strategic partnerships positions it well for future growth. Recent financial performance highlights a positive trajectory, with increasing revenues and improving profit margins. The strong liquidity and market capitalization further enhance the company's appeal to potential investors.
AI Generated • Jul 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

830

CEO

Samira Sakhia, MBA

Website

www.gud-knight.com

Headquarters

Montreal, QC H4M 2P2, CA

KHTRF Financials

Key Financial Metrics (TTM)

Gross Margin

37.32%

Operating Margin

2.70%

Net Income Margin

1.10%

Return on Equity

0.73%

Return on Capital

-0.26%

Return on Assets

0.52%

Earnings Yield

0.60%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$689.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

98.18M

Volume

7.90K

Avg. Volume

9.15K

Financials (TTM)

Gross Profit

CA$190.67M

Operating Income

CA$13.79M

EBITDA

CA$65.26M

Operating Cash Flow

CA$105.65M

Capital Expenditure

-CA$29.38M

Free Cash Flow

CA$76.27M

Cash & ST Invst.

CA$127.62M

Total Debt

CA$69.96M

Knight Therapeutics Performance Analysis

Knight Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 225,496,18916.1%
20232023-12-31CAD 243,166,7557.8%
20242024-12-31CAD 271,032,41811.5%
20252025-12-31CAD 322,115,28218.8%
Knight Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3021.9%
Q32025-09-3013.4%
Q42025-12-319.3%
Q12026-03-3111.9%
Knight Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.20N/A
20232023-12-31CAD -0.12-41.9%
20242024-12-31CAD 0.03N/A
20252025-12-31CAD -0.04N/A
Knight Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-750.0%
Q32025-09-3070.7%
Q42025-12-31334.1%
Q12026-03-3145.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$148.82M

+69.0%

Gross Profit

CA$54.58M

+56.5%

Gross Margin

36.67%

N/A

Market Cap

$689.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$830.98K

N/A

Employees

830

N/A

Net Income

CA$13.20M

+504.3%

EBITDA

CA$26.84M

+107.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$127.62M

-29.4%

Total Debt

CA$69.96M

+29.7%

Accounts Receivable

CA$157.02M

+25.1%

Inventory

CA$142.28M

+1.5%

Long Term Debt

CA$48.29M

+62.6%

Short Term Debt

CA$21.61M

-10.8%

Return on Assets

0.52%

N/A

Return on Invested Capital

1.54%

N/A

Free Cash Flow

CA$37.22M

+120154.6%

Operating Cash Flow

CA$40.55M

+1004.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AGYTFAllergy Therapeutics plc
$0.15+0.00%
VRNOFVerano Holdings Corp.
$1.30+8.33%
PTCHFPureTech Health plc
$1.53+0.00%
VHIBFVitalhub Corp.
$4.89-0.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About KHTRF

What is the current price of Knight Therapeutics?

Knight Therapeutics is trading at $7.03 per share.

What is the 52-week range for Knight Therapeutics?

Over the past 52 weeks, Knight Therapeutics has traded between $4.07 and $7.40.

How much debt does Knight Therapeutics have?

As of the most recent reporting period, Knight Therapeutics reported total debt of CA$50.00M.

How much cash does Knight Therapeutics have on hand?

Knight Therapeutics reported CA$77.42M in cash and cash equivalents in its most recent financial results.

What is Knight Therapeutics’s dividend yield?

Knight Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services